| Some types of potential indicators of the tumor primary chemosensitivity | Relation with the progression-free survival (PFS) | Relation with the progression-free survival (PFS) | Relation with the progression-free survival (PFS) | the disadvantages of the application to the management of ovarian cancers |
| Pathology examination Chemotherapy response score (CRS) on surgery specimen | In the adnexal and omentum,CRS3 related to better PFS compared to CRS1/2 |
| Evaluating the tumor structure and tumor microenvironment | The demand for tumor tissue after chemotherapy limits the possibility of adjusting disease management plan before surgery |
| The level of tumor-infiltrating lymphocytes (TILs) | A high CD8(+)/FoxP3(+) ratio and high levels of CD8 (+) TILs related to better disease-free survival | Higher levels of intraepithelial TILs related to better OS | Suitable for most of solid tumors | The demand for tumor tissue limits the possibility of adjusting disease management plan before surgery |
| BRCA1 or BRCA 2 mutations | Patients with BRCA mutations related to higher PFS | Patients with BRCA mutations related to higher OS | Higher benefit from PARP inhibitors | Higher benefit from PARP inhibitors |
| Homologous recombination deficient (HRD) status | HRD-positive Patients related to higher PFS |
| HRD-positive Patients related to higher PFS | Difficulties for building a validated panel with HR-related genes due to many unknown genes. |
| Modeled CA-125 kinetic parameter, KELIM | Difficulties for building a validated panel with HR-related genes due to many unknown genes. | Difficulties for building a validated panel with HR-related genes due to many unknown genes. | Low cost, high availability. | Abnormal CA-125 >35 IU/L at baseline |